Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News

Mexican Jalapenos Tied to Salmonella Outbreak in 27 US States

U.S. health officials are investigating a Salmonella outbreak linked to Mexican jalapeno peppers that has sickened 345 people in 27 states, prompting supplier ⁠Coast Citrus...

US Cyclosporiasis Probe Linked to Lettuce Widens to 15 States

U.S. health authorities have widened their probe into a cyclosporiasis outbreak tied to iceberg lettuce from central Mexico after detecting cases in six additional states,...

Genetic Marker Linked to Severe Outcomes Across IBD Subtypes

HLA-DRB1*01:03 may serve as a genetic marker for severe outcomes across IBD phenotypes and help identify patients at higher risks for surgery and treatment failure.

Does High-Dose Vitamin D3 Supplementation Improve CRC Survival?

A phase 3 trial was conducted to confirm the benefit of high-dose vitamin D3 supplementation in patients with previously untreated metastatic CRC that was seen in a phase 2 trial.

IV Vitamin C With Chemo Shows Signals in Cancer Care

A phase 2 study reported a longer median overall survival in patients receiving IV ascorbate with chemotherapy, although larger randomized trials are needed to confirm the finding.

Small Colorectal Lesions Carry Risk for Deep Invasion

Non-pedunculated colorectal lesions smaller than 2 cm may harbor deep submucosal invasion despite their diminutive size, study finds.

Todays Updates

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Todays Updates

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Latest News

U.S. health officials are investigating a Salmonella outbreak linked to Mexican jalapeno peppers that has sickened 345 people in 27 states, prompting supplier ⁠Coast Citrus...

U.S. health authorities have widened their probe into a cyclosporiasis outbreak tied to iceberg lettuce from central Mexico after detecting cases in six additional states,...

HLA-DRB1*01:03 may serve as a genetic marker for severe outcomes across IBD phenotypes and help identify patients at higher risks for surgery and treatment failure.

A phase 3 trial was conducted to confirm the benefit of high-dose vitamin D3 supplementation in patients with previously untreated metastatic CRC that was seen in a phase 2 trial.

A phase 2 study reported a longer median overall survival in patients receiving IV ascorbate with chemotherapy, although larger randomized trials are needed to confirm the finding.

Non-pedunculated colorectal lesions smaller than 2 cm may harbor deep submucosal invasion despite their diminutive size, study finds.

News All Time

CRC Screening in Adults Under 50: Research Reveals Trends

After colorectal cancer screening guidelines were updated in 2021 to lower the screening age to 45, three studies look at how providers are reaching those patients.

Simple Risk Score Is the Best at Detecting Liver Fibrosis

The LiverRisk score outperformed the fibrosis-4 index for detecting moderate or greater fibrosis across all age groups, particularly in younger adults.

How to Predict Iron Therapy Response in IBD

Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.

‘A Tiny Blueberry’: How Ingestible Sensors Keep Shrinking

A new thermometer is powerful, accurate, and easily swallowed even by children. Inside the push to make the perfectly sized, perfectly powered ingestible device.

Anxiety May Undermine Treatment Response in Some GERD Cases

Higher anxiety is linked to poorer response to proton pump inhibitor treatment among patients with gastroesophageal reflux disease.

Older Adults Have Worse Lower GI Bleeding Outcomes

Older adults with lower gastrointestinal bleeding present with more severe disease and substantially higher 30-day mortality—yet most deaths stem not from bleeding itself, but from decompensation of underlying chronic conditions.

Vaccine to Prevent Pancreatic Cancer Shows Early Promise

The vaccine spurs a lasting immune response in people at a high risk for pancreatic cancer. Whether it staves off the disease remains to be seen.

Durvalumab Tied to Extended Biliary Tract Cancer OS Benefit

Researchers examine 4-year outcomes of the phase 3 TOPAZ-1 study.

Low-Volume PEG Wins for Inpatient Bowel Cleansing

PEG 1 L beats ‘more-is-better’ pre-colonoscopy regimens, demonstrating more high-quality cleansing and greater tolerability than 2-L and 4-L formulations.

Why the Painless Abdominal Bloating in Middle-Age Man?

Admitted for pyelonephritis, but his diagnostic journey is just beginning

Beware Aspiration Risk in Chronic Pot Users

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Unusual Confluence of Two Rare Syndromes Results in Peculiar Symptoms

Interpretation of an ultrasound exam made all the difference in creating a treatment plan

Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

— Results highlight importance of careful evaluation of concurrent medications, researchers say

Q&A: Managing GI Toxicities of Immunotherapy

Gastrointestinal side effects are among the most important issues to address with patients starting on immune checkpoint inhibitors.

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Recommended News For You

Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients

Study finds 81% of cancer cures touted by TikTok videos are fake

Assisted Dying Under Scrutiny From Medscape's Readers

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

Mapping lifelong chronic health risks for childhood cancer survivors

Adding cell-based vaccine to liver cancer therapy can slow cancer progression

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Recommended Articles For You

Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes 

Rehabilitation Following Bone Marrow Functional Suppression: Clinical Strategies and Advances 

Survival Rate Dynamics in Hematologic and Solid Malignancies 

Everything You Need to Know About HTLV: A Comprehensive Guide  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo causes lasting physical decline in breast cancer survivors

2.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

3.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

4.

Which women need more than mammograms for breast cancer screening?

5.

Cancer research in the US is world class. With the government pulling out, its future is uncertain

1.

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care

2.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

3.

Prevention of Thrombotic Complications in High-Risk Patients

4.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

5.

Personalized Survivorship Navigation in Precision Cancer Care

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

2.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

5.

Case-Based Learning: Oncology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot